ALK and non-small cell lung carcinoma: More recently, a phase II study of ceritinib in previously treated patients with ALK-rearranged NSCLC found an intracranial ORR of 45.0% (95% CI, 23.1% to 68.5%) among the 100 patients with baseline BM [14].